New biotech company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines
AdaptVac is a joint venture between ExpreS2ion Biotechnologies and NextGen Vaccines. AdaptVac combines ExpreS2ion’s platform with novel proprietary and ground-breaking viral capsid-like particle (CLP) technology developed at the University of Copenhagen.
AdaptVac’s Capsid-Like Particle (CLP) will be employed to deliver an optimal vaccine against the SARS-CoV-2 virus ( COVID-19) with the goal to have the vaccine complete initial human clinical testing to show safety and efficacy within 12 months.
According to Wian de Jongh, AdaptVac’s CEO, the unique strength of the company's technology is that it makes any vaccine look like a virus to the body’s immune system. This gives the optimal stimulus to generate a fast immune response, followed by long-lasting and highly-efficacious protection. The principle is similar to the successful US FDA and European EMA approved HPV vaccine. The consortium members working on the vaccine strongly believe that the technology will be a key player in global emergencies, such as the COVID 19 epidemic.
The PREVENT-nCoV consortium members (below) are world-leading experts in their respective fields, covering all relevant areas of viral research and vaccine development required for rapid clinical development of a COVID-19 vaccine:
- Institute for Tropical Medicine (ITM) at University of Tübingen
- Department of Medical Microbiology, Leiden University Medical Center
- Department of Immunology and Microbiology, University of Copenhagen
- ExpreS2 ion Biotechnologies
- Laboratory of Virology, Wageningen University.